Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
Why the study?
Despite strong evidence of cardiovascular benefit, uptake of newer glucose-lowering medications has been low, prompting evaluation of global trends and predictors of SGLT2i and GLP-1 RA use.
Population
14,576 patients with type 2 diabetes initiating second-line therapy across 37 countries
Comparison
Use of SGLT2i or GLP-1 RA vs non-use
Design
Global prospective observational study
Follow-up
3 years
Authors
Discussion
Loading...
Member takes
Implication
Suboptimal uptake with marked country-level variation persists independent of clinical factors; leaves open drivers of disparities for targeted implementation research.
Structured PICO
P
Population
14,576 patients with type 2 diabetes from 37 countries enrolled at initiation of second-line glucose-lowering therapy
I
Intervention
SGLT2 inhibitors or GLP-1 receptor agonists
O
Outcome
Use of either an SGLT2 inhibitor or GLP-1 receptor agonist at last follow-up and country-level variability
Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes remains suboptimal and highly variable across countries, independent of patient clinical factors.
Cite This Study
Arnold et al. (2022) studied this question.